AbCellera Biologics (ABCL) Return on Invested Capital (2021 - 2023)
Historic Return on Invested Capital for AbCellera Biologics (ABCL) over the last 3 years, with Q4 2023 value amounting to 0.16%.
- AbCellera Biologics' Return on Invested Capital fell 2800.0% to 0.16% in Q4 2023 from the same period last year, while for Dec 2023 it was 0.16%, marking a year-over-year decrease of 2800.0%. This contributed to the annual value of 0.23% for FY2024, which is 600.0% down from last year.
- AbCellera Biologics' Return on Invested Capital amounted to 0.16% in Q4 2023, which was down 2800.0% from 0.14% recorded in Q3 2023.
- In the past 5 years, AbCellera Biologics' Return on Invested Capital registered a high of 0.19% during Q3 2022, and its lowest value of 0.16% during Q4 2023.
- For the 3-year period, AbCellera Biologics' Return on Invested Capital averaged around 0.03%, with its median value being 0.11% (2022).
- Per our database at Business Quant, AbCellera Biologics' Return on Invested Capital crashed by -300bps in 2022 and then plummeted by -3200bps in 2023.
- AbCellera Biologics' Return on Invested Capital (Quarter) stood at 0.14% in 2021, then decreased by -21bps to 0.11% in 2022, then crashed by -246bps to 0.16% in 2023.
- Its Return on Invested Capital stands at 0.16% for Q4 2023, versus 0.14% for Q3 2023 and 0.1% for Q2 2023.